> Alzheimer disease is a neurodegenerative disease affecting an increasing number of patients worldwide. Current therapeutic strategies are direc'/> Molecular characterization of the <fc >β</fc>β ‐amyloid(4‐10) epitope of plaque specific <fc >Aβ</fc>Aβ antibodies by affinity‐mass spectrometry using alanine site mutation
首页> 外文期刊>Journal of peptide science: An official publication of the European Peptide Society >Molecular characterization of the ββ ‐amyloid(4‐10) epitope of plaque specific Aβ antibodies by affinity‐mass spectrometry using alanine site mutation
【24h】

Molecular characterization of the ββ ‐amyloid(4‐10) epitope of plaque specific Aβ antibodies by affinity‐mass spectrometry using alanine site mutation

机译:使用丙氨酸位点突变通过亲和质谱法的斑块特异性Aβ-/ Fc>Aβ抗体的ββ-蛋白(4-10)表位的分子表征

获取原文
获取原文并翻译 | 示例
           

摘要

> Alzheimer disease is a neurodegenerative disease affecting an increasing number of patients worldwide. Current therapeutic strategies are directed to molecules capable to block the aggregation of the β‐amyloid(1‐42) (Aβ) peptide and its shorter naturally occurring peptide fragments into toxic oligomers and amyloid fibrils. Aβ‐specific antibodies have been recently developed as powerful antiaggregation tools. The identification and functional characterization of the epitope structures of Aβ antibodies contributes to the elucidation of their mechanism of action in the human organism. In previous studies, the Aβ(4‐10) peptide has been identified as an epitope for the polyclonal anti‐Aβ(1‐42) antibody that has been shown capable to reduce amyloid deposition in a transgenic Alzheimer disease mouse model. To determine the functional significance of the amino acid residues involved in binding to the antibody, we report here the effects of alanine single‐site mutations within the Aβ‐epitope sequence on the antigen‐antibody interaction. Specific identification of the essential affinity preserving mutant peptides was obtained by exposing a Sepharose‐immobilized antibody column to an equimolar mixture of mutant peptides, followed by analysis of bound peptides using high‐resolution MALDI‐Fourier transform‐Ion Cyclotron Resonance mass spectrometry. For the polyclonal antibody, affinity was preserved in the H6A, D7A, S8A, and G9A mutants but was lost in the F4, R5, and Y10 mutants, indicating these residues as essential amino acids for binding. Enzyme‐linked immunosorbent assays confirmed the binding differences of the mutant peptides to the polyclonal antibody. In contrast, the mass spectrometric analysis of the mutant Aβ(4‐10) peptides upon affinity binding to a monoclonal anti‐Aβ(1‐17) antibody showed complete loss of binding by Ala‐site mutation of any residue of the Aβ(4‐10) epitope. Surfa
机译: >阿尔茨海默病是一种影响全世界患者数量越来越多的神经变性疾病。目前的治疗策略涉及能够阻断β-淀粉样蛋白(1-42)(Aβ)肽的聚集的分子及其较短的天然存在的肽片段中的毒性低聚物和淀粉样蛋白原纤维。最近已经开发了β特异性抗体作为强大的抗凝聚工具。 Aβ抗体表位结构的鉴定和功能表征有助于阐明它们在人体中的作用机制。在先前的研究中,已鉴定Aβ(4-10)肽作为多克隆抗Aβ(1-42)抗体的表位,其已经表明能够在转基因阿尔茨海默病小鼠模型中降低淀粉样蛋白沉积。为了确定参与与抗体结合的氨基酸残基的功能意义,我们在此报告丙氨酸单位点突变在Aβ表位序列内对抗原 - 抗体相互作用的影响。通过将琼脂糖固定化抗体柱暴露于突变肽的等摩尔混合物,然后使用高分辨率马尔达 - 傅里叶变换离子回转质谱法分析结合肽来获得本质亲和力保存突变肽的具体鉴定。对于多克隆抗体,在H6A,D7A,S8A和G9A突变体中保留亲和力,但在F4,R5和Y10突变体中丢失,表明这些残基作为结合的必需氨基酸。酶联免疫吸附试验证实突变肽与多克隆抗体的结合差异。相反,突变Aβ(4-10)肽对单克隆抗Aβ(1-17)抗体结合的突变Aβ(4-10)肽的质谱分析显示出Aβ的任何残留物的ALA现场突变的完全丧失(4 -10)表位。 Surfa.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号